Sevelamer Carbonate
Product Images NDC 71335-3021

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 71335-3021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713353021)

Label for Sevelamer Carbonate tablets 800 mg by Bryant Ranch Prepack. The label states storage instructions, dosage referral via QR code, and packaging in a tight container. It indicates a package size of 50 tablets, Rx only, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Macleods Pharmaceuticals Ltd.*

FDA Label Image

Sevelamer-car-structure (Sevelamer Carbonate Fig 1)

Chemical structure diagram of Sevelamer Carbonate showing the molecular components including NH3+, HCO3-, NH2, and hydroxyl groups in a polymeric arrangement.*

FDA Label Image

Figure-2 (Sevelamer Carbonate Fig 2)

A forest plot comparing the effect of Sevelamer Carbonate versus placebo across various subgroups. The y-axis lists subgroups such as Screening BSA, Baseline Serum Phosphorus, Age, and Dialysis status, while the x-axis quantifies the effect difference with confidence intervals. Data points indicate most subgroup results favor Sevelamer Carbonate over placebo.*

FDA Label Image

Figure-3 (Sevelamer Carbonate Fig 3)

A line graph depicting the percentage of patients with at least a 2-fold reduction versus the reduction in serum phosphorus (mg/dL). It compares two treatments labeled Sevelamer Hydrochloride and Active Control, showing the relationship between serum phosphorus reduction and patient response.*

FDA Label Image

Figure-4 (Sevelamer Carbonate Fig 4)

A line graph comparing phosphorus change from baseline over 52 weeks between Sevelamer Hydrochloride and an active control. The x-axis represents study weeks, and the y-axis represents phosphorus change from baseline. Both treatments show an initial decrease in phosphorus, stabilizing over time with minimal variance between them.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.